Loading...

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

2:53

Pharmaceutical Executive Daily: Moonwalk Biosciences'...

Pharmaceutical Executive ·

2026/09/08

Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity platform, and Sebastian Arana of MilliporeSigma talks through the real cost of manufacturing flexibility.

en-us

2:49

Pharmaceutical Executive Daily: FDA Approves Zanvastro

Pharmaceutical Executive ·

2026/09/04

Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical Executive’s weekly biotech roundup gathers analyst reaction to the week's biggest stories, and Nate Hill of Strive Pharmacy talks through the regulatory uncertainty around compounded peptides.

en-us

3:24

Pharmaceutical Executive Daily: Ultragenyx's...

Pharmaceutical Executive ·

2026/09/03

Ultragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research talks through the mechanics of analyzing linked real-world data sets, and Melanie Whittington joins The Ron Lanton Report to argue biopharma policy needs to stay tethered to patients, not abstractions.

en-us

38:27

The Ron Lanton Report: What Are We Doing This All For?

Pharmaceutical Executive ·

2026/09/03

Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, joins Ron Lanton to argue that biopharmaceutical policy only makes sense when traced back to its purpose.

en-us

3:10

Pharmaceutical Executive Daily: Novartis and BMS Halt...

Pharmaceutical Executive ·

2026/09/02

Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials over safety concerns, a dealmaking roundup covers Alteogen's licensing deal with Novartis, NewBiologix's gene therapy partnership with Synastra, and RedHill's acquisition of Rebyota and Clenpiq from Ferring, and Lexi Cogswell and Tom Rotolo make the case for real-world insights in obesity medical strategy.

en-us

3:26

Pharmaceutical Executive Daily: Nine Companies Strike...

Pharmaceutical Executive ·

2026/09/01

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA flu vaccine into Phase III, and Simcere Zaiming licenses its tri-specific antibody Sim0660 to Roche for up to $1.53 billion.

en-us

3:01

Pharmaceutical Executive Daily: Eli Lilly Enters $2.8...

Pharmaceutical Executive ·

2026/08/31

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer immunotherapy Cevumeran, and Parth Khanna argues that more competitive data doesn't mean better intelligence in pharma.

en-us

3:45

Pharmaceutical Executive Daily: DualityBio and Teva...

Pharmaceutical Executive ·

2026/08/28

FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major biopharma deals, and Israel Ortiz makes the case for preventive maintenance in manufacturing.

en-us

3:10

Pharmaceutical Executive Daily: President Trump...

Pharmaceutical Executive ·

2026/08/27

Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs make it to market, and the Trump administration opens a new round of Medicaid drug pricing deals.

en-us

3:34

Pharmaceutical Executive Daily: Haisco Licenses...

Pharmaceutical Executive ·

2026/08/26

A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major licensing deals with SK Biopharmaceuticals and Sentivera, and Raviv Pryluk makes the case for rethinking clinical trial sample sizing.

en-us

2:58

Pharmaceutical Executive Daily: FDA Approves Imaavy...

Pharmaceutical Executive ·

2026/08/25

FDA approves Imaavy as the first treatment for warm autoimmune hemolytic anemia, McKesson agrees to acquire Precision Medicine Group as Lundbeck partners with Eversana on AI-driven commercialization, and Adam Bartley examines how integrated GMP operating models are reshaping outsourced manufacturing.

en-us

3:31

Pharmaceutical Executive Daily: Hanmi Licenses...

Pharmaceutical Executive ·

2026/08/24

Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most nominated peptides for the compounding bulks list, and Ivo Carre examines how tau- and microglia-targeted therapies are reshaping the Alzheimer's pipeline beyond amyloid.

en-us

3:18

Pharmaceutical Executive Daily: Amplitude...

Pharmaceutical Executive ·

2026/08/21

Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's Dan Chancellor makes the case for dealmaking as a survival skill, and this week's rare disease approvals and a $322 million biosimilar deal reveal where pharma strategy is heading.

en-us

3:24

Pharmaceutical Executive Daily: FDA Approves Pasatru

Pharmaceutical Executive ·

2026/08/20

A partnership roundup covers deals from IntraGel Therapeutics/UroGen Pharma and Lupin/Tenpoint Therapeutics, FDA approves Regeneron's Pasatru for fibrodysplasia ossificans progressiva, and RELEX's Rohit Tripathi discusses reshoring pharma manufacturing.

en-us

3:13

Pharmaceutical Executive Daily: President Trump to...

Pharmaceutical Executive ·

2026/08/19

President Trump moves to nominate Heidi Overton as FDA commissioner, Ron Lanton weighs in on drug pricing's collision with trade policy, and Mohd Haque looks at how pharma leaders are scaling AI across the drug lifecycle.

en-us

3:14

Pharmaceutical Executive Daily: Unpacking IRA-Driven...

Pharmaceutical Executive ·

2026/08/18

LEO Pharma, BioMarin, OmniAb, and Chugai post a busy week of pharma dealmaking, RELEX's Rohit Tripathi weighs in on who ultimately pays for tariff-driven input costs, and Spherix Global Insights' Sybil Mead unpacks IRA-driven formulary pressure spreading across payer portfolios.

en-us

2:57

Pharmaceutical Executive Daily: Henlius and Sandoz...

Pharmaceutical Executive ·

2026/08/17

Henlius and Sandoz ink a biosimilars collaboration, ADVI's Tyler Seville makes the case for 340B reform, and RELEX's Rohit Tripathi weighs in on what real pharma reshoring requires.

en-us

2:57

Pharmaceutical Executive Daily: Pharm Exec Ranks Top...

Pharmaceutical Executive ·

2026/08/14

Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated approval for multiple myeloma, and PwC's Glenn Hunzinger talks the shifting economics of pharma dealmaking.

en-us

3:00

Pharmaceutical Executive Daily: 2026 Emerging Pharma...

Pharmaceutical Executive ·

2026/08/13

A funding roundup covers new IPO and Series A raises across Silence Therapeutics, AbCellera, Beyang Therapeutics, and Remepy, Tyler Seville of ADVI examines the policy concerns building around the 340B Drug Pricing Program, and Pharmaceutical Executive names its 2026 Emerging Pharma Leaders.

en-us

3:06

Pharmaceutical Executive Daily: Mereo BioPharma...

Pharmaceutical Executive ·

2026/08/12

Mereo BioPharma licenses its lung disease treatment alvelestat to Sentynl Therapeutics, Krieger Scientific's Joseph Morwald examines what's driving a surge in FDA warning letters, and IQVIA's Christopher Wooden and Tom Woods make the case for persona-based HCP engagement.

en-us

459 results

Similar Podcasts

Beyond the Divide

Koala Moon

The SCP Experience

Dr. NoSleep Studios

John Michael Godier"s Event Horizon

John Michael Godier

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media